Publication: Multimodal imaging of bacterial-host interface in mice and piglets with Staphylococcus aureus endocarditis
No Thumbnail Available
Date
2020-11-04
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
American Association for the Advancement of Science (AAAS)
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Panizzi, Peter, Marvin Krohn-Grimberghe, Edmund Keliher, Yu-Xiang Ye, Jana Grune, Vanessa Frodermann, Yuan Sun, et al. “Multimodal Imaging of Bacterial-Host Interface in Mice and Piglets with Staphylococcus Aureus Endocarditis.” Science Translational Medicine 12, no. 568 (November 4, 2020): eaay2104. https://doi.org/10.1126/scitranslmed.aay2104.
Research Data
Abstract
Acute bacterial endocarditis is a rapid, difficult to manage and frequently lethal disease. Even potent antibiotics often cannot efficiently kill Staphylococcus aureus (S. aureus) that colonizes the heart’s valves. S. aureus relies on virulence factors to evade therapeutics and the host’s immune response. For instance, S. aureus usurps the host’s clotting system by activating circulating prothrombin with staphylocoagulase and von Willebrand factor-binding protein. An insoluble fibrin barrier then forms around the bacterial colony, shielding the pathogen from immune cell clearance. Targeting virulence factors may provide new avenues to better diagnose and treat endocarditis. To tap into this unused therapeutic opportunity, we co-developed therapeutics and multimodal molecular imaging to probe the host-pathogen interface. We introduced and validated a family of small-molecule optical and PET reporters targeting active thrombin in the fibrin-rich environment of bacterial colonies. The imaging agents, based on the clinical thrombin inhibitor dabigatran, bound to heart valve vegetations in mice. Aortic or tricuspid S. aureus endocarditis in piglets was successfully imaged with clinical PET/MRI. We employed optical imaging to monitor therapy with antibodies neutralizing staphylocoagulase and von Willebrand factor binding protein in mice with S. aureus endocarditis. This treatment deactivated bacterial defenses against innate immune cells, decreased in vivo imaging signal and improved survival. Our data map a route towards adjuvant immunotherapy for endocarditis and provide efficient tools to monitor this drug class for infectious diseases.
Description
Other Available Sources
Keywords
General Medicine
Terms of Use
Metadata Only